RESUMO
BACKGROUND: Development of therapeutic approaches for rare respiratory diseases is hampered by the lack of systems that allow medium-to-high-throughput screening of fully differentiated respiratory epithelium from affected patients. This is a particular problem for primary ciliary dyskinesia (PCD), a rare genetic disease caused by mutations in genes that adversely affect ciliary movement and consequently mucociliary transport. Primary cell culture of basal epithelial cells from nasal brush biopsies followed by ciliated differentiation at the air-liquid interface (ALI) has proven to be a useful tool in PCD diagnostics but the technique's broader utility, including in pre-clinical PCD research, has been restricted by the limited number of basal cells that can be expanded from such biopsies. METHODS: We describe an immunofluorescence screening method, enabled by extensive expansion of basal cells from PCD patients and the directed differentiation of these cells into ciliated epithelium in miniaturised 96-well transwell format ALI cultures. As proof-of-principle, we performed a personalised investigation in a patient with a rare and severe form of PCD (reduced generation of motile cilia), in this case caused by a homozygous nonsense mutation in the MCIDAS gene. RESULTS: Initial analyses of ciliary ultrastructure, beat pattern and beat frequency in the 96-well transwell format ALI cultures indicate that a range of different PCD defects can be retained in these cultures. The screening system in our proof-of-principal investigation allowed drugs that induce translational readthrough to be evaluated alone or in combination with nonsense-mediated decay inhibitors. We observed restoration of basal body formation but not the generation of cilia in the patient's nasal epithelial cells in vitro. CONCLUSION: Our study provides a platform for higher throughput analyses of airway epithelia that is applicable in a range of settings and suggests novel avenues for drug evaluation and development in PCD caused by nonsense mutations.
Assuntos
Transtornos da Motilidade Ciliar , Síndrome de Kartagener , Cílios , Transtornos da Motilidade Ciliar/diagnóstico , Transtornos da Motilidade Ciliar/tratamento farmacológico , Transtornos da Motilidade Ciliar/genética , Avaliação Pré-Clínica de Medicamentos , Ensaios de Triagem em Larga Escala , Humanos , Síndrome de Kartagener/diagnóstico , Síndrome de Kartagener/tratamento farmacológico , Síndrome de Kartagener/genética , Depuração MucociliarRESUMO
Expression of inducible nitric oxide synthase (iNOS) is generally accompanied by a parallel upregulation in l-arginine transport which is dependent, at least in part, on the synthesis of new carrier proteins. It is not clear however whether the induction of iNOS and its subsequent utilisation of l-arginine for NO synthesis contribute to the enhancement in l-arginine transport rates observed following induction of cells with pro-inflammatory mediators. To address this issue, we have transfected an iNOS construct in a pEGFP-N1 vector into HEK-293 cells and investigated the effects this has on l-arginine transport. The expression of iNOS through transfection resulted in the production of significant quantities of NO as detected by the standard Griess assay. Under these conditions, the transport of l-arginine was found to be unaltered, with rate of uptake being comparable in both transfected and non-transfected cells. Characterisation of the transporter(s) involved with uptake of l-arginine revealed features characteristic of the classical cationic amino acid transport system y(+). Further analysis of the expression profile of the cationic amino acid transporter (CAT) involved revealed the presence of transcripts for CAT-1 and CAT-2B. These data demonstrate that iNOS activity does not drive or enhance l-arginine transport despite the fact that HEK-293 cells transport l-arginine via the CATs, including CAT-2B which is thought to be critical for supply of substrate to iNOS.
Assuntos
Arginina/metabolismo , Óxido Nítrico Sintase/genética , Sequência de Aminoácidos , Animais , Transporte Biológico/fisiologia , Transportador 1 de Aminoácidos Catiônicos/genética , Transportador 1 de Aminoácidos Catiônicos/fisiologia , Transportador 2 de Aminoácidos Catiônicos/genética , Transportador 2 de Aminoácidos Catiônicos/fisiologia , Linhagem Celular , Clonagem Molecular , DNA Complementar/análise , Perfilação da Expressão Gênica , Proteínas de Fluorescência Verde/genética , Proteínas de Fluorescência Verde/metabolismo , Humanos , Concentração de Íons de Hidrogênio , Rim/citologia , Rim/efeitos dos fármacos , Rim/metabolismo , Dados de Sequência Molecular , Óxido Nítrico/biossíntese , Óxido Nítrico Sintase/metabolismo , Óxido Nítrico Sintase Tipo II , Oligopeptídeos/farmacologia , RNA Mensageiro/genética , RNA Mensageiro/metabolismo , Ratos , Sódio/farmacologiaRESUMO
The mode of action of the essential oil of Coleonema album, a South African species from the Cape region, was studied on smooth muscle in vitro using field-stimulated guinea-pig ileum. The oil produced an initial spasmogenic activity followed by spasmolysis, both actions being dose-dependent. The spasmolytic action was post-synaptic and not atropine-like and was unaffected by the adrenoceptor blockers phentolamine and propranolol. There was no evidence for the involvement of either cyclic guanosine monophosphate or cyclic adenosine monophosphate in the spasmolytic activity. The oil had some calcium channel blocking activity but this is not the primary explanation for its spasmolytic response. Antimicrobial activity against Pseudomonas aeruginosa, Escherichia coli, Staphyloccocus aureus and Saccharomyces cerevisiae was very low and totally absent against Enterococcus hirae, suggesting that the oil has no worthwhile potential in this area. However, as the oil has a very disagreeable odour in its undiluted form, it could be a powerful insect repellent, as its local usage suggests, and this remains to be investigated.